Effect of Theta Burst Transcranial Magnetic Stimulation on Patients with Dysphagia After Stroke
Launched by ZHANG XIAOHUI · Jun 21, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18-80 years old
- • The first stroke lasted from 2 weeks to 6 months, with stable vital signs and right-handedness
- • The stroke met the diagnostic criteria of "Chinese Guidelines for the Diagnosis and Treatment of Cerebral Hemorrhage 2019" or "Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018" formulated by the Cerebrovascular Department of the Branch of Neurology of the Chinese Medical Association, and the cerebral CT or MRI examination showed unilateral cerebral infarction or cerebral hemorrhage.
- • The dysphagia was consistent with the Expert Consensus on the Evaluation and Treatment of dysphagia in China (2017 edition), and the dysphagia was confirmed by videofluoroscopic swallowing study.
- • MMSE\>24, good cognitive function
- • The skull is intact without craniotomy or repair
- • Subject or family members sign informed consent
- Exclusion Criteria:
- • Combined with other diseases that may cause swallowing disorders, such as Parkinson's disease, dementia, motor neurone disease and other neurological diseases, or esophageal, neck surgery and other diseases that cause swallowing organ structure abnormalities
- • A history of mental illness or epilepsy
- • A metal implant in the head or eye, a pacemaker or a drug pump in the body
- • Pregnancy, malignant tumor, serious disease history of heart, liver, kidney and other important organs
- • Ulceration or infection of the skin on the head or where the electrode is applied
- • Poor compliance and inability to complete basic treatment
About Zhang Xiaohui
Zhang Xiaohui is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in the clinical research landscape, Zhang emphasizes rigorous study design, ethical standards, and regulatory compliance to ensure the integrity and reliability of trial results. By fostering collaboration with healthcare professionals and leveraging innovative methodologies, Zhang Xiaohui aims to contribute valuable insights to the scientific community and support the development of new therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported